![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
E Dahlberg, A Thalen, R Brattsand, JA Gustafsson, U Johansson, K Roempke and T Saartok
The affinity for the glucocorticoid receptor in rat skeletal muscle of some glucocorticoids with a new type of 16 alpha, 17 alpha-acetal substituent has been estimated and correlated to the glucocorticoid activities in three in vivo systems in rats. Budesonide (an approximately 1:1 mixture of the C(22) epimers of 11 beta, 21-dihydroxy- 16 alpha, 17 alpha-[(22R,S)-propylmethylenedioxy]-pregna-1,4-diene-3,20- dione) and the isolated (22R)- and (22S)-epimers bound to the same binding site as the potent glucocorticoids dexamethasone (DEX) or triamcinolone 16 alpha, 17 alpha-acetonide (TA), but with even higher affinity than DEX or TA, despite the lack of a 9 alpha-fluoro atom in budesonide and its epimers. The (22R)-epimer was twice as active as the (22S)-epimer, 4 times more active than TA, and 14 times more active than DEX. The introduction of a 9 alpha-fluoro atom slightly decreased the binding affinity of the (22R)-epimer of budesonide, in contrast to the positive effect of 9 alpha-fluorination of, e.g., 16 alpha, 17 alpha-acetonides. The negative influence of 9 alpha-fluorination of the (22R)-epimer was partially reversed in the 6 alpha, 9 alpha- difluorinated (22R)-epimer. Nevertheless, the fluorinated compounds were more active than DEX and TA (8 and 11 times more active than DEX, and 2 and 3 times more active than TA, in case of the 9 alpha-fluoro- and 6 alpha, 9 alpha-difluoro-derivatives of the (22R)-epimer, respectively). Budesonide is metabolized mainly to 16 alpha- hydroxyprednisolone (11 beta, 16 alpha, 17 alpha, 21-tetrahydroxy- pregna-1,4-diene-3,20-dione) and 6 beta-hydroxy-budesonide. Both metabolites were very weak competitors for the ligand-binding sites on the receptor (3% and 6% of the affinity of DEX, respectively). The affinity for the receptor in vitro was closely correlated to the topical glucocorticoid activity in vivo for the 12 steroids compared (r = 0.98; R = 0.98), which supports the contention that in vitro tests for receptor affinity are useful when screening for agonists among steroids with the present type of structures. The results on receptor- ligand interaction are in accordance with X-ray crystallographic data available for some steroids.
This article has been cited by other articles:
|
|
 |
|
  R. Hermann, W. Siegmund, T. Giessmann, K. Westphal, A. Weinbrenner, B. Hauns, F. Reutter, G. Lahu, K. Zech, and T. D. Bethke The Oral, Once-Daily Phosphodiesterase 4 Inhibitor Roflumilast Lacks Relevant Pharmacokinetic Interactions With Inhaled Budesonide J. Clin. Pharmacol., August 1, 2007; 47(8): 1005 - 1013. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sahasranaman, M. Issar, and G. Hochhaus METABOLISM OF MOMETASONE FUROATE AND BIOLOGICAL ACTIVITY OF THE METABOLITES Drug Metab. Dispos., February 1, 2006; 34(2): 225 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. Fardon, D. K. C. Lee, K. Haggart, L. C. McFarlane, and B. J. Lipworth Adrenal Suppression with Dry Powder Formulations of Fluticasone Propionate and Mometasone Furoate Am. J. Respir. Crit. Care Med., November 1, 2004; 170(9): 960 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. N Hofer Oral Budesonide in the Management of Crohn's Disease Ann. Pharmacother., October 1, 2003; 37(10): 1457 - 1464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. AHRENS, M. E. TERESI, S.-H. HAN, D. DONNELL, J. A. VANDEN BURGT, and C. R. LUX Asthma Stability after Oral Prednisone . A Clinical Model for Comparing Inhaled Steroid Potency Am. J. Respir. Crit. Care Med., October 1, 2001; 164(7): 1138 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. MILLER-LARSSON, P. JANSSON, A. RUNSTROM, and R. BRATTSAND Prolonged Airway Activity and Improved Selectivity of Budesonide Possibly Due to Esterification Am. J. Respir. Crit. Care Med., October 1, 2000; 162(4): 1455 - 1461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Lipworth Systemic Adverse Effects of Inhaled Corticosteroid Therapy: A Systematic Review and Meta-analysis Arch Intern Med, May 10, 1999; 159(9): 941 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Hall, S. Lim, I. R. Witherden, T. D. Tetley, P. J. Barnes, A. M. Kamal, and S. F. Smith Lung type II cell and macrophage annexin I release: differential effects of two glucocorticoids Am J Physiol Lung Cell Mol Physiol, January 1, 1999; 276(1): L114 - L121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Miller-Larsson, H. Mattsson, E. Hjertberg, M. Dahlbäck, A. Tunek, and R. Brattsand Reversible Fatty Acid Conjugation of Budesonide. Novel Mechanism for Prolonged Retention of Topically Applied Steroid in Airway Tissue Drug Metab. Dispos., July 1, 1998; 26(7): 623 - 630. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. R. Greenberg, B. G. Feagan, F. Martin, L. R. Sutherland, A. Thomson, C. N. Williams, L.-G. Nilsson, T. Persson, and The Canadian Inflammatory Bowel Disease Study Grou Oral Budesonide for Active Crohn's Disease N. Engl. J. Med., September 29, 1994; 331(13): 836 - 841. [Abstract] [Full Text]
|
|
|
|
|
|
P. Rutgeerts, R. Lofberg, H. Malchow, C. Lamers, G. Olaison, D. Jewell, A. Danielsson, H. Goebell, O. O. Thomsen, H. Lorenz-Meyer, et al. A Comparison of Budesonide with Prednisolone for Active Crohn's Disease N. Engl. J. Med., September 29, 1994; 331(13): 842 - 845. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
